Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sean Maloney, Anajane Smith, Daniel E. Furst, David Myerson, Kate Rupert, Paul C. Evans, J. Lee Nelson
Published in Volume 104, Issue 1
J Clin Invest. 1999; 104(1):41–47 doi:10.1172/JCI6611
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

HLA-B44–specific PCR of DNA extracted from PBMCs of a 49-year-old scleroderma patient who was B44-negative and whose mother was B44-positive. Lanes 3 and 5 are patient samples from 2 different draw dates. Lane 7 is a positive control from the mother, and lane 8 is a positive control from a homozygous cell line. The patient’s HLA-B alleles were B*0801 and B*3508, and lanes 10 and 11 are negative controls derived from homozygous cell lines with these alleles. Lane 12 is a negative reagent control, and lanes 2, 4, 6, and 9 are blank.